EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

Simultaneous Tumor Shrinkage and Bronchial Perforation Induced by Nivolumab plus Cabozantinib Combination Therapy in a Patient with Collecting Duct Carcinoma

Hiroki Okumura, Kyoko Murase, Suguru Oka, Rika Kizawa, Takeshi Yamaguchi, Yuko Tanabe, Koichi Suyama, Kazushige Sakaguchi, Shinji Urakami, Yuji Miura

Chemotherapy · 2024

DOI: 10.1159/000534470 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Chemotherapy, 2024. Verfasst von Hiroki Okumura und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan, pbuu59vj@gmail.com. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Anilides, Pyridines. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vascular endothelial growth factor receptor tyrosine kinase inhibitors are known to cause perforation as one of their severe side effects, and postoperative and postradiation therapy are known risk factors. However, there are few studies on perforation following tumor shrinkage. A 78-year-old woman with postoperative recurring left collecting duct carcinoma of the right hilar lymph nodes and mediastinum underwent eight courses of nivolumab plus cabozantinib, resulting in tumor shrinkage. Three days after the last administration, she developed fever and cough and was hospitalized for right lobar pneumonia. The patient received long-term antibiotics for bronchial fistula with the destruction of the bronchial wall and secondary lung abscess. When using nivolumab plus cabozantinib combination therapy for a tumor with bronchial invasion, physicians should be aware of bronchial perforation as the tumor shrinks.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsAnilidesPyridinesFemaleHumansAgedNivolumabVascular Endothelial Growth Factor ANeoplasm Recurrence, Local

Stichwörter der Autor:innen

AbscessCollecting duct carcinomaFistulaImmune checkpoint inhibitorsVascular endothelial growth factor receptor tyrosine kinase inhibitor

Substanzen

NivolumabcabozantinibVascular Endothelial Growth Factor AAnilidesPyridines

Autor:innen und Institutionen

  • Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan, pbuu59vj@gmail.com.
  • Department of Respiratory Medicine, Respiratory Center, Toranomon Hospital, Tokyo, Japan.
  • Department of Urology, Toranomon Hospital, Tokyo, Japan.
  • Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan.

Zitieren

APA

Okumura, H., Murase, K., Oka, S., Kizawa, R., Yamaguchi, T., Tanabe, Y., Suyama, K., Sakaguchi, K., Urakami, S., & Miura, Y. (2024). Simultaneous Tumor Shrinkage and Bronchial Perforation Induced by Nivolumab plus Cabozantinib Combination Therapy in a Patient with Collecting Duct Carcinoma. Chemotherapy. https://doi.org/10.1159/000534470

Vancouver

Okumura H, Murase K, Oka S, Kizawa R, Yamaguchi T, Tanabe Y, et al. Simultaneous Tumor Shrinkage and Bronchial Perforation Induced by Nivolumab plus Cabozantinib Combination Therapy in a Patient with Collecting Duct Carcinoma. Chemotherapy. 2024. doi:10.1159/000534470

BibTeX
@article{Okumura2024,
  author = {Okumura, Hiroki and Murase, Kyoko and Oka, Suguru and Kizawa, Rika and Yamaguchi, Takeshi and Tanabe, Yuko and Suyama, Koichi and Sakaguchi, Kazushige and Urakami, Shinji and Miura, Yuji},
  title = {Simultaneous Tumor Shrinkage and Bronchial Perforation Induced by Nivolumab plus Cabozantinib Combination Therapy in a Patient with Collecting Duct Carcinoma},
  journal = {Chemotherapy},
  year = {2024},
  doi = {10.1159/000534470}
}
Kostenlos starten →